Similarly, checkpoint blockade therapy (anti-PD-1, anti-PD-L1, anti-CTLA-4) corrects nutrient restriction experienced by T cells in a progressing tumor by upregulating CD28 mediated glycolysis (Figure 2C) [50]. Here, CD274 is linked to neoplasm.